Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adaptive dose finding single phase 2b clinical trial of psilocybin assisted psychotherapy ("PAP") in people diagnosed with treatment resistant depression

Next Previous
X
Search
Trial Profile

Adaptive dose finding single phase 2b clinical trial of psilocybin assisted psychotherapy ("PAP") in people diagnosed with treatment resistant depression

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Psilocybin (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 13 Oct 2021 According to a MYND Life Sciences media release, the company's proprietary biomarker test technology will be a pivotal component of this trial seeking partial funds from a $15 million fund allocated by the Australian government.
    • 13 Oct 2021 According to a MYND Life Sciences media release, this project will be led by Professor Paul Fitzgerald, of Monash University with 7 scientific collaborators from Monash University, Deakin University and the University of Sydney.
    • 13 Jul 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top